Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.25 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.49M
Market Cap
$11.28B
Enterprise Value$13.47B
Total Cash (Recent Filing)$233.00M
Total Debt (Recent Filing)$455.10M
Price to Earnings (P/E)34.6
Beta0.55
Next Earnings
Apr 30, 2025EPS Estimate
0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding99,703,530
10 Day Avg. Volume1,408,158
30 Day Avg. Volume1,494,921
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)N/A
Price to Sales (P/S)4.79
Price to Cash Flow (P/CF)11.60
P/FCF Ratio11.60
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda22.07
Forecast
1Y Price Target
$167.38Price Target Upside47.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Crenessity ProspectsA majority of responders expect a peak penetration for Crenessity of 50% in adults and up to 77.5% in pediatric patients.
Stock OpportunityThe recent selloff has created a nice buying opportunity for NBIX.
Bears Say
Ingrezza ChallengesIngrezza's Q1 to be impacted by a number of headwinds, but prospects for long-term growth remain intact.
---
Ownership Overview
1.08% Insiders
23.42% Mutual Funds
24.45% Other Institutional Investors
23.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $110.25 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $11.28B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Apr 30, 2025 which is in 54 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 06, 2025. The company reported $1 earnings per share for the quarter, missing the consensus estimate of $1.606 by -$0.606.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.86.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,703,530 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1 in its last earnings report, missing expectations of $1.606. Following the earnings report the stock price went down -18.53%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$167.38 (47.02% Upside)
$167.38 (47.02% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.82%
12-Months-Change
Fundamentals
Return on Equity
14.16%
Trailing 12-Months
Asset Growth
15.53%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$167.38
▲(47.02% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+9.09%
reiterated a buy rating 4 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +9.09% per trade.
---